Examples of using VHIO in English and their translations into Spanish
{-}
-
Colloquial
-
Official
Vall d'Hebron Institute of Oncology(VHIO), Barcelona Science Park(PCB)
Finally, Peptomyc, a spin-off of the Vall d'Hebron Institute of Oncology(VHIO), is working with an oncogene inhibitor(Omomyc-CPP)
The Vall d'Hebron Institute of Oncology(VHIO) and the BBVA Foundation have presented a Comprehensive Cancer Immunotherapy
director of Project Management at Gendiag; Jordi Rodon, doctor in the Vall d'Hebron University Hospital(VHIO) Medical Oncology Department,
Vall d'Hebron Institute of Oncology(VHIO) just published in the journal Nature Communications a pioneering study that demonstrated for the first time the analysis of cerebrospinal fluid(LCR)
director of Project Management at Gendiag; Jordi Rodon, a doctor from the Vall d'Hebron University Hospital(VHIO) Medical Oncology Department,
the Vall d'Hebron Institute of Oncology(VHIO), are leading this event that will bring together world-renowned researchers to debate the advances in improving prevention
the Vall d'Hebron Institute of Oncology(VHIO), which together with VHIR is part of Accredited Institute of Campus Vall d'Hebron Institute by the Institute of Health Carlos III ISCIII.
VHIO is a leading comprehensive cancer center.
María Abad, who joined VHIO last summer[…].
Seoane is the director of the VHIO Translational Research Program.
clinical researchers in VHIO.
Laura Soucek, research professor at the Vall d Hebron Institute of Oncology VHIO.
Regarding the RHCP index, the VHIO stands out with 10,286 with 525 documents.
VHIO Scientific Manager is a pioneer in translational research.
Facilitate clinical-molecular correlative studies at VHIO.
The VHIO has some of the most dynamic cancer research programmes in Spain.
More clinical studies: VHIO will be the first center in Spain to offer an international clinical trial with CAR cells exclusively for lymphomas.
The VHIO has also published a study demonstrating the efficacy of a biomarker to identify patients resistant to PARP inhibitors in the Annals of Oncology.
Of the 16 centers selected in Europe, VHIO is the first authorized to include patients.